Five syngeneic transplants were performed in four patients following myeloablative therapy using unmodified peripheral blood mononuclear cells (PBMCs) collected after the administration of recombinant human granulocyte colony stimulating factor (rhG-CSF) to normal donors. The only toxicity experienced by the four normal donors was bone pain. Four patients received two collections of PBMCs, and a second transplant was performed in one patient with one collection. The patients received a median of 20.53 X 1 O8 total nucleated cells/kg (range 20 to 25.5). 1 1.3 X I O 8 total mononuclear cells/kg (range 6.52 to 17.2), 1 13.1 X 104/kg CFU-GM (range 46.7 to 211.8) and 9.6 X I O 6 CD34+ cells/kg (range 1.6 to 12.6) Post-transplant growth factors were not administered. The median time to an absolute neutrophil count greater than 0.5 X 109/L UTOLOGOUS PERIPHERAL blood mononuclear A cells (PBMCs) collected after the administration of recombinant human granulocyte colony stimulating factor (rhG-CSF) results in prompt and probably durable engraftment after myeloablative therapy.* Allogeneic transplants using PBMCs collected after rhG-CSF administration may provide a substitute for aspirated bone marrow cells. Available data from autologous transplants suggests that allogeneic PBMCs could provide for more rapid neutrophil and platelet engraftment, reducing platelet requirements after transplant and ultimately reducing the cost and length of the hospital stay. Additionally, the morbidity associated with PBMC collection may be less than with traditional bone marrow harvests.24 As a preliminary step to allografting with PBMCs, the results of five syngeneic transplants in four patients using PBMC's collected from syngeneic normal donors after the administration of rhG-CSF were analyzed and are reported here.
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PATIENTS AND METHODS
Four patients with syngeneic donors were referred to the Fred Hutchinson Cancer Research Center (FHCRC) for consideration of marrow transplantation. As an alternative to marrow harvest, normal donors were offered the alternative of receiving rhG-CSF followed by the collection of PBMCs by leukapheresis. Informed consent was obtained using protocols and forms approved by the FHCRC institutional review board for patients and donors.
Four normal donors underwent the administration of rhG-CSF (Amgen, Thousand Oaks, CA) by subcutaneous injection (16 pg/ kg) daily for 4 days. Leukapheresis using a percutaneous Mahurkar catheter was initiated 18 to 24 hours following the third dose of rhG-CSF and performed on 2 consecutive days. RhG-CSF was administered after leukapheresis on day 4. The donor for unique patient number (UPN) 7382 underwent a second PBMC collection using a vein-to-vein technique 60 days after collections for the first transplant. One leukapheresis was performed on day 5 of rhG-CSF administration. This second transplant was performed as consolidation treatment. UPN 7382 had normal peripheral blood counts at was 14 days (range 10 to 18). The median time to platelet transfusion independence was 11 days (range 10 to 13). Two patients had the number of CD3+ T lymphocytes determined in the pheresis product. An average of 3.04 X 10'' CD3' cells were collected per pheresis. This represents an approximate 1 log increase over the number of T lymphocytes in a typical bone marrow transplant. Rh-GCSF can be used to mobilize peripheral blood progenitor cells from normal donors with minimal toxicity. Studies of allogeneic transplants using PBMCs collected after rhG-CSF administration to determine permanent grafting ability and the incidence and severity of graft-versus-host disease are warranted. that time. Leukapheresis was performed with the use of automated continuous-flow blood cell separators (Spectra; Cobe Laboratories, Engelwood, Co. CS-3000; Fenwal lnc, Round Lake, IL) as previously described.' CD34* cells in the leukapheresis product were measured as previously described.' Lymphocyte quantities were measured in all samples in the following manner. A I mL sample of the leukapheresis product was hemolyzed with ammonium chloride hemolytic buffer and washed twice with phosphate buffered saline containing 2% human AB serum, and aliquoted into tubes at 1 X lo6 cells per tube. Each tube was incubated with either CD3, CD4, CD8, CD19, or CD20 monoclonal antibody conjugated to phycoerythrin or fluorescein for 20 minutes at 2 2 T , then washed twice. Cells were analyzed on a FACSCAN (Becton-Dickinson, Palo Alto, CA) and the data analyzed using a cell analysis program (Reproman; Truefacts Software Inc, Seattle, WA). From the analysis of forward and 90 light scatter, a gate was established to include all white blood cells, excluding platelets and red blood cells. A second gate was established to include only lymphocytes and mononuclear cells, excluding granulocytes. The cells in the second gate were analyzed for fluorescence of cells labeled with the particular MoAb. The percentage of cells labeled was then multiplied by the total white blood cell count to give a concentration of antibody + cells in the product. This concentration of tagged cells was then multiplied by the volume of product collected to give the total number in the product. Colonyforming units-granulocyte-macrophage (CFU-GM) were measured by plating 1 X lo5 peripheral blood mononuclear cells in a 1.25% methylcellulose solution containing IO% lymphocyte-conditioned media, 10% human plasma, 20% fetal calf serum, 9% Iscoves media, and 5 x mol/L M2-mercaptoethanol. Colonies of greater than 50 cells were counted on an inverted microscope after 14 days.
The characteristics of the four patients receiving syngeneic PBMC transplants are shown in Table 1 . Patients received 1 of 3 different preparative regimens followed by the infusion of noncryopreserved PBMCs as the sole source of stem cells on each of 2 successive days immediately following the collections. Day 0 was the day of first PBMC infusion. Post-transplant growth factors were not administered.
Supportive care included private rooms, red blood cell and platelet transfusion, and antibiotics as previously de~cribed,~ except for the second transplant in one patient (UPN 7382B), which was performed entirely in the outpatient department. Daily complete blood cell counts were performed and time to engraftment was assessed by determining the day after transplant on which patients achieved 0.1, 0.5, 1.0 neutrophils X IO9 and 20 X IO9 platelets/L; independent of transfusion support.
RESULTS

Eflect of PBMC collection on normal donors. All four
normal donors received a short Mahurkar catheter placed percutaneously without complications. PBMCs were collected for the second transplant for patient UPN 7382 using a standard vein-to-vein technique. There were no catheterrelated infections or thromboses in the four normal donors. All four normal donors reported minor bone pain during the 5-day administration of rhG-CSF, and this was relieved by acetaminophen in all cases. There were no additional side effects observed during or following the administration of rhG-CSF.
PBMC collection characteristics. The number of total nucleated cells (TNC), total mononuclear cells (TMC), CFU-GM, and CD34+ cells collected with 2 consecutive collections are shown in Table 2 . The values for patient UPN 7382B are from a single collection. The number of T lymphocytes were determined in the PBMC collections for patient UPN 7382B and 7440. The PBMC collection contained an average of 3.04 X 10" (4.5 X 108/kg) CD3+, 1.80 X IO" (2.6 X 10s/kg) CD4+, and 0.99 X 10" (1.4 X 108/kg) CD8' lymphocytes per pheresis. Table 3 shows the engraftment characteristics of the five syngeneic transplants. When compared with a historical control group of 12 patients receiving autologous rhG-CSFmobilized PBMCs, there was no difference in time to ANC greater than 0.1, greater than 0.5, greater than 1.0, or to platelets greater than 20 X 109/L. One patient (UPN 7440) experienced a decrease in the platelet count to 25 x 109/L on day +32, after initially achieving platelet transfusion independence on day + 1 1 and a peak platelet count of 170 X 109/L on day + 19. This patient had no evidence of infection, and was not taking any medications that could explain the abrupt drop in her platelet count. She received a platelet transfusion on day +32 and day +35. Her platelet count has increased steadily and was 68 X 109/L on day +43.
DISCUSSION
Transplants with PBMCs have several advantages compared with bone marrow. PBMCs appear to result in faster engraftment of neutrophils and platelets than does marrow, or marrow plus post-transplant GM-CSF in the autologous ~etting.~.' Additional advantages of PBMCs include a decrease in platelet and red blood cell transfusions, a decrease in the duration of hospital stay, and a reduction in the cost of transplantation. Before proceeding with allogeneic PBMC transplants, the ability to harvest PBMCs from normal donors without complications, and a measurement of the number of T lymphocytes collected should be determined because the number of donor T lymphocytes transplanted may have an impact on both sustained engraftment and graft-versus-host disease. Much of this information can be obtained from autologous PBMC transplants, especially in patients with limited chemotherapy exposure. However, evaluation of syngeneic transplants is a logical step before proceeding with allogeneic transplants using PBMCs.
The toxicity of rhG-CSF 16 pg/kg/day for 5 days was evaluated on five occasions in four syngeneic normal donors. The only toxicity observed in these donors was minor bone pain relieved by acetaminophen in all cases. No catheter-related infections or thromboses were encountered. In a previous study, we reported a lack of side effects in eight normal donors given rhG-CSF (3.5-6 pg/kg/day) for 9 to 14 days before the collection of granulocytes.' Feldman et a19 have also reported a lack of toxicity in 8 normal donors given rhG-CSF 5 pg/kg/day before granulocyte collections. Although no acute toxicities of rhG-CSF were observed and no long-term consequences are expected, unusual late complications cannot be ruled out without further follow-up. We previously reported that a mean of 7.3 k 4.3 X IO6 CD34+ cells/kg and 20.5 k 28.1 X lo4 CFU-GM/kg collected after rhG-CSF administration resulted in prompt and durable neutrophil and platelet engraftment in autologous recipients following marrow ablative therapy.' In that study, all patients experienced neutrophil engraftment before day 15; however, two patients did not become platelettransfusion-independent until day +49 and day +70. These two patients had the lowest number of CD34+ cells collected 0.5 and 1.6 X IO6 CD34+ cells/kg, respectively. The lowest number of syngeneic CD34' cells infused was 1.6 X 106/kg, but this was not associated with delayed platelet recovery. It is unclear whether the delayed platelet transfusion recovery observed after autologous PBMC infusion is a result of an inadequate number of stem cells collected, or whether the stem cells may have been damaged by previous chemoradiation. Further analysis concerning the predictive value of the number of CD34' cells infused is ongoing.
The question of whether PBMCs mobilized by rhG-CSF will result in permanent engraftment can only be resolved by direct evaluation of allogeneic transplantation. In the absence of genetic markers, it remains unknown as to whether the infusion of autologous or syngeneic marrow or PBMCs contributes to long-term engraftment because residual host stem cells surviving the marrow ablative regimen could be responsible for long-term recovery after myeloablative therapy. It is unlikely that further follow-up of the current four syngeneic recipients will be of value concerning this question because we have not observed late graft failure in recipients of autologous PBMCs receiving the same myeloablative regimens.
Studies of PBMC transplants in animals suggest that PBMCs can provide for long-term multilineage hematopoiesis. Molineaux et a1" performed sex-mismatched allogeneic transplants in mice with G-CSF-mobilized PBMCs. After 10 months of follow-up, they were able to show that donor cells were present in the blood, spleen, thymus, and bone marrow of recipient mice. Fliedner et al"." and Storb et all3 have shown that the cells present in allogeneic PBMC collections are capable of hematopoietic reconstitution in lethally irradiated dogs. In the Fliedner studies, one dog survived over 791 days with confirmed donor cells. These studies show that the cells present in PBMC collections can provide for multilineage lymphohematopoiesis in mice and dogs for 1 to 2 years.
Only one study of allogeneic PBMC transplant has been performed in a human. This patient experienced rapid trilineage engraftment confirmed to be of donor origin at 27 days post-transplant, but subsequently died of infe~ti0n. l~ We have determined that the number of lymphocytes expressing the CD3 antigen present in PBMCc collected after the administration of rhG-CSF is between 1.99 and 5.61 X lo'', or approximately 22% of the TNCs ~ollected.~ This represents an approximate 1 log increase in the number of T lymphocytes in PBMC collections compared with marrow, where 1 to 2 X lo9 total T lymphocytes are typically collected. The average number of T lymphocytes collected in the pheresis product of two normal donors was 3.04 X 10" as measured by CD3+ cells. Therefore, it may be advantageous to limit PBMC collections to one procedure because there is a doubling of the lymphocyte quantity with each collection.
Based on an analysis of platelet recovery after autologous PBMC transplants, we have set the minimum dose of CD34+ cells for autografting at 5.0 X 106/kg (unpublished observations). The dose of CD34+ PBMCs necessary for allografting is unknown but is likely to be greater than for autografts. For autologous marrow transplants we attempt to obtain a minimum of 1 X 108/kg of TMCs compared with 3 X 10' for allogeneic transplants. Based on this empiric ratio, the collection of 15.0 X 106/kg of CD34' cells would be a reasonable goal. With appropriate timing this should be feasible with one collection by leukapheresis. The effect on graft-versus-host disease of increased numbers of T lymphocytes present in PBMC collections is unknown. Strategies such as T-cell depletion or CD34+ selection may be necessary if the increased numbers of T lymphocytes present in the rhG-CSF-mobilised PBMC products are found to be associated with increased graft-versus-host disease. 
